VEGFA and retinopathy of prematurity: Moreover, the effect of reduced doses of bevacizumab on the ocular and systemic side effects was not evaluated in this study; though many studies have investigated different doses of anti-VEGF for ROP patients, systemic absorption remains a major concern [9, 16].